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Abstract
There has been a resurgence in home haemodialysis over the last decade and interest
in online haemodiafiltration in gaining momentum with advances in technology and
the  results  of  recent  clinical  trials.  Both  increasing  haemodialysis  frequency  and
treatment time have a number of potential benefits in improving dialysis efficiency and
are ideally placed in the home setting. This chapter describes the rationale behind
dialysis treatments, which go beyond conventional haemodialysis (CHD) and future
avenues for home dialysis, which may involve combining convective therapy with more
frequent treatment.
Keywords: haemodialysis, haemodiafiltration, extended haemodialysis, home haemo‐
dialysis
1. Introduction
Haemodialysis treatment has changed the lives of millions of patients around the world who
have advanced kidney disease.  The treatment  has  advanced considerably  since  the  first
treatment on a human, lasting just 15 minutes and performed by George Haas in Giessen,
Germany, in October 1924 [1]. It was not until the 1960s when maintenance haemodialysis
really started and at present, over 90 years since Haas, there are over 400,000 prevalent users
in the USA alone [2]. Dialysis provides a bridge to transplantation for some, and for others, it
allows survival when residual kidney function is no longer sufficient to sustain life. While the
survival  of  patients  has  improved since  the  early  days  of  its  inception,  the  survival  of
haemodialysis patients remains unacceptably poor. In the United Kingdom, 18% of those aged
65–74 starting haemodialysis will not survive 1 year [3]. Five‐year survival data has often been
compared to those of patients with cancer to make the figures more tangible. With recent
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figures showing 50% survival at 5.8 years in the 55–64 years group [4], it is not hard to see why
this comparison is made. Clearly, one of the key challenges for the nephrology community is
to change this unacceptably high mortality rate. In addition to this, there are many other factors
that make a large difference to the patient in front of us, and arguably, these are as impor‐
tant to address and considerably improve.
2. Background
The aim of haemodialysis is to replicate normal physiology as much as possible. Although this
may sound straightforward initially, there are a vast array of factors to consider. The ideal
treatment should give good survival rates, prevent cardiovascular events and hospitalizations,
effectively manage fluid and salt balance and address the anaemia and mineral‐bone disorder
associated with chronic kidney disease (CKD). Patient well‐being, cognition, sleep, the ability
to work and nutritional status are also hugely important factors which need addressing and
the list could continue. For a treatment, which for the majority of patients is performed for 12
hours of the week (just 7% of the week in terms of time), this is an incredibly tall order and it
is not entirely surprising that outcomes remain poor.
Conventional haemodialysis (CHD) is the most common treatment schedule and lasts for 3–4
hours thrice weekly. This treatment mainly takes place in a hospital or in a dedicated dialysis
unit. Other treatment regimes include short daily haemodialysis (SDHD), which is performed
for 1.5–3 hours 5–7 times per week, long nocturnal daily haemodialysis (LNDHD) which is
performed for 6–8 hours 5–7 times per week and long conventional haemodialysis (LHD),
which is typically 8 hours 3 times per week.
Although CHD is the most common treatment regime now, LHD was the most common
treatment initially in the 1960s [5]. This treatment came about purely by convention. Home
haemodialysis in the United Kingdom was started in London in 1964 by Shaldon and his team
[6] and expanded following this. Home haemodialysis was necessary as hospital facilities were
sparse, treatment times were lengthy and home dialysis offered both financial and logistical
benefit. Prevalence in the United Kingdom peaked in 1982 when 62% of HD patients were at
home [3]. As dialysis treatment time shortened and patient numbers increased, haemodialysis
practice changed from a predominantly home‐based therapy to a predominantly hospital‐
based therapy.
The National Cooperative Dialysis Study (NCDS) (n = 151) [7] was published in 1981. It showed
no difference between the shorter and longer duration dialysis groups (2.5–3.5 hours three
times per week vs. 4.5–5 hours three times per week). This further paved the way to the
adoption of CHD. Data from this study were later used to develop a method for calculating
haemodialysis adequacy [8] Kt/Vurea (Kt/V) which is now used worldwide. Kt/V exclusively looks
at small molecule clearance as a marker of dialysis adequacy. There is an association between
dialysis dose and mortality [9]; however, the benefit (from the NCDS data) was seen up until
a Kt/V of 1.2 with no survival advantage with doses above this. This was later echoed in the
much larger HEMO study (involving 1846 patients) and again showed no advantage in
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increasing the dialysis dose above a Kt/V of 1.3. Dialysis treatment time was not investigated
in this study.
It would seem therefore that with Kt/V we have reached a ceiling where improvements can no
longer be made within the restrictions of a thrice weekly schedule, and we must start looking
at other ways to improve outcomes in haemodialysis. The most significant causes of death in
haemodialysis patients are cardiovascular in nature and this has been well known for some
time. UK registry data show that almost a third of deaths in dialysis patients are cardiovascular
in nature [4]. It is also clear that the two‐day gap in CHD is harmful with all‐cause and
cardiovascular mortality being higher on the day after the long interval [10]. Further data show
the highest rate of cardiovascular events in the first month after starting haemodialysis and a
high‐risk period extending to 4 months [11].
Based on all of this, a strong argument can be made to further explore more frequent and
extended haemodialysis treatments.
3. Extracorporeal dialysis therapy
The basic principle behind dialysis is the removal of solutes across a semipermeable mem‐
brane. Haemodialysis relies on the process of diffusion where solutes move from an area of
high concentration to an area of low concentration. Solutes pass from the patients’ blood to
the dialysis fluid across the dialysis membrane in this manner. The concentration gradient is
maintained by the countercurrent flow of dialysate and blood and the maintenance of adequate
blood and dialysate flow.
Haemofiltration allows the clearance of larger molecules through the process of convection. A
hydrostatic pressure gradient is used to pass the patient's blood across a membrane with a
large pore size. Solutes follow water through a process called “solvent drag” [12]. Large
volumes of fluid are typically filtered and a replacement fluid is required, which enters the
dialysis circuit and is mixed with the patient's blood before it is returned.
Haemodiafiltration (HDF) combines the techniques of both haemodialysis and haemofiltra‐
tion. Solutes are cleared by both diffusion and convection, thus allowing more efficient
clearance of both small and middle molecules. The replacement fluid can either be obtained
from pre‐prepared bags or prepared “online” by the machine (OL‐HDF), which is able to
produce ultrapure fluid. This dialysis therapy has a number of potential advantages, which
are discussed in more detail later in this chapter.
3.1. Clearance in extracorporeal dialysis
Kt/V is widely used to give us information on dialysis adequacy; however, it is solely dependent
on the clearance of urea. Urea has the advantage of being easy to measure; however, it may
not be directly toxic and many of the identified uraemic toxins are larger in size and are not
cleared efficiently by conventional haemodialysis [13]. In general, molecules are classified as
small molecular weight (MW) molecules (<500 Da), middle MW molecules (>500 Da) and
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protein‐bound molecules. β2‐microglobulin (B2M), which is commonly used as a marker of
middle molecules, has a molecular weight of around 11,800 Da. It has been demonstrated that
outcomes are improved when middle molecular clearance (1000–50,000 Da in the study) are
enhanced [14]. There has been much interest in increasing middle MW molecule clearance,
and it is clear that accumulation of middle MW molecules can be harmful such as in the case
of B2M which can lead to dialysis‐related amyloidosis [15].
β‐Trace protein, cystatin‐C and B2M are all middle MW molecules that are freely filtered,
resorbed and catabolized in the tubular cells. A study by Lindström et al. [16] has shown clear
differences in the clearance of these molecules by different dialysis modalities—CHD did not
change the concentrations of any of these proteins while in HDF both cystatin C and B2M were
reduced and β‐trace protein was only reduced in HDF. This demonstrates a clear difference
between dialysis modalities in terms of clearance and a clear biomarker that could be meas‐
ured. Moreover, β‐trace protein had been found to be an independent predictor of both death
and cardiovascular mortality in haemodialysis patients [17]. The use of such molecules could
be part of the way that we assess haemodialysis adequacy in the future and tailor treatment
to the patient.
3.2. Biocompatibilty in dialysis
The specifications of dialysis membranes have improved considerably. The use of cellulose‐
based membranes were common initially; however, they were associated with complement
and leucocyte activation [18] resulting in dialyser reactions. The majority of dialysis mem‐
branes in use now are synthetic and are more biocompatible—reactions can still occur however
and anaphylactoid reactions have been reported, particularly in patients on ACE inhibitors
[19]. More recently, dialysis membranes have been manufactured with larger pore sizes to
allow a higher ultrafiltration rate and allow clearance of larger molecules. Membranes can be
classified as high flux or low flux and for the purposes of the HEMO study [20] were defined
as B2M clearances of <10 ml/min for low flux and >20 ml/min for high flux. High‐flux mem‐
branes have been found to lower pre‐dialysis B2M concentrations [21] and may prevent
dialysis‐related amyloidosis [22]. Several observational studies have identified a survival
benefit with high‐flux dialysers [23, 24]. Although the HEMO study showed no benefit from
high‐flux membranes, the study may not have been sufficiently powered to detect a significant
benefit [25]. The subsequent European study, the MPO Study [26], showed survival benefit to
those patients with a serum albumin of <40 g/l. Several guidelines now recommend high‐flux
dialysers including the European Renal Association [27] and practice has also changed
considerably.
The production of a high‐quality infusion fluid is of paramount importance in HDF. More than
20 litres of infusion fluid can be administered to the patient during a typical HDF session and
thus ultrapure water and dialysis fluid are required. Ultrapure water is defined by the standard
for replacement fluid requiring <0.1 colony‐forming units (CFU)/ml and an endotoxin
concentration <0.03 endotoxin unit (EU)/ml [28]. The use of ultrapure dialysis fluid is associ‐
ated with a reduction in inflammatory markers and an improvement in serum albumin,
haemoglobin and ferritin [29].
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4. Increasing haemodialysis frequency and length with home
haemodialysis
The seminal paper in 1992 by Bernard Charra and his group in Tassin, France, showed hugely
impressive survival rates of their haemodialysis patients of 87% at 5 years and 43% at 20 years,
which far surpassed matched patients on both European and US registries. All patients
received 8 hours of haemodialysis three times per week (LHD). It is likely that the survival
association is related to achieving good blood pressure control (antihypertensives were seldom
required in the group) through optimized ultrafiltration and the enhanced clearance of
uraemic toxins provided by the longer treatment. Their publication sparked interest once again
in extended haemodialysis. With the continued increasing demand for renal replacement
therapy and limited resources in hospitals, novel ways of providing haemodialysis were
required. Home haemodialysis seemed an attractive option and could also accommodate more
frequent and extended schedules. The first daily nocturnal haemodialysis programme was set
up in Toronto in 1994 [30].
The prescription of home haemodialysis in the United Kingdom remains very variable;
however, the most common prescription in 2009 was still 4 hours thrice weekly (51.9% of home
HD patients), followed by alternate day dialysis (20.5%), short daily (17.4%) and nocturnal
(2.9%) [31]. This is a surprising finding given the benefits of more frequent and extended
haemodialysis (which we will now expand on). This does however reflect patient choice and
the comfort of both patients and clinicians with a CHD schedule.
4.1. The benefits of extended and more frequent haemodialysis
Several benefits have come to light from more frequent and extended haemodialysis and these
will be outlined in this section.
4.1.1. Survival, cardiovascular outcomes and hospitalizations
Observational studies show a significant mortality benefit associated with home haemodial‐
ysis, even when adjustments are made for age and comorbidity [32]. These findings are also
apparent in studies in Australia and New Zealand [33], which have a higher uptake of home
haemodialysis. Figures of 90% survival at 5 years and 45% at 20 years have been quoted [34].
Figure 1 shows a clear survival advantage to home haemodialysis over both peritoneal dialysis
and facility‐based HD. These data have to be interpreted with care given the high number of
confounders. Patients selected for home haemodialysis are generally younger with a low
comorbidity burden. They are usually highly motivated and take an interest in their healthcare.
The frequent haemodialysis network (FHN) trials were setup to give a more definitive answer
to the benefits of more frequent and extended haemodialysis [35, 36]. The SDHD arm of the
trial randomized 245 patients to either frequent (6 times per week) or conventional haemo‐
dialysis and the nocturnal arm randomized 87 patients to either CHD or LDNHD. Two
coprimary composite endpoints were used—death or change in LV mass or death or change
in physical‐health composite score. There was a favourable outcome with regard to both
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coprimary endpoints for the SDHD trial but not with the LNDHD trial. Looking purely at
survival, there was no significant benefit from either trial. With a 12‐month follow‐up period
and the numbers involved with the trials, they were not powered to detect an effect on
mortality. The question therefore still remains unanswered as to whether more frequent and
extended haemodialysis does have a favourable effect on survival.
Figure 1. The survival of home HD patients in New Zealand compared with facility HD and peritoneal dialysis (PD).
Image adapted from Marshall et al. [35].
There is an associated reduction in cardiovascular‐related admissions in converting patients
from CHD to LDNHD [37]. There are also fewer cardiovascular‐associated hospital admissions
associated with SDHD compared with matched CHD; however, all‐cause hospitalizations
remain unchanged [38]. The FHN studies once again showed no change in the rate of hospi‐
talizations.
4.1.2. Ultrafiltration and blood pressure control
There is a strong association between a high ultrafiltration rate (>10 ml/kg/hour) and mortality
[39, 40]. Chronic fluid overload contributes to an increased LV mass and congestive cardiac
failure [41] and this is likely to be highly significant in terms of cardiovascular morbidity and
mortality. Increasing haemodialysis treatment time improves the tolerance of ultrafiltration
[42, 43]. There are also many reports of improved blood pressure control both in LNHD and
in SDH [44–46] and a regression of left ventricular hypertrophy [47]. It has also been shown
that ejection fraction, in those with heart failure, can be improved through more frequent
haemodialysis and ultrafiltration [48]. With CHD, it often the case that dry weight is not
achieved. Patients that experience hypotension during haemodialysis often have their
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ultrafiltration stopped, receive saline infusions and thus never achieve their dry weight and
in fact can exacerbate the situation further. Extended dialysis allows much lower ultrafiltration
rates and thus less haemodynamic disturbance. It is likely the effect that extended dialysis has
on blood pressure goes beyond the optimization of volume status. When compared to patients
on CHD, some patients with a high extracellular volume (measured by bioimpedance) but on
extended haemodialysis achieve normotension [49]. A theory put forward for this phenom‐
enon is that extended haemodialysis may lead to efficient removal of vasoactive factors that
contribute to hypertension.
4.1.3. Small molecule clearance
Increasing haemodialysis frequency provides more efficient clearance of small MW molecules.
It provides a lower peak urea, lower mean urea and less fluctuation [50]. This provides a lower
time‐averaged concentration (TAC). Looking purely at Kt/V would, however, be misleading
as this would remain the same despite the enhanced clearance.
4.1.4. Phosphate balance
There is a clear association between raised serum phosphate and adverse cardiovascular
outcomes in patients with CKD [51, 52]. Conventional haemodialysis does provide sufficient
phosphate removal for western diets, and as a result, there is a net phosphate gain [53]. As a
result of this, multiple phosphate binder tablets are often required to reduce the absorption of
phosphate from the gut. On average, haemodialysis patients have an average pill burden of
19 pills per day and many of these are phosphate binders [54]. A higher pill burden in this
setting is associated with lower quality of life scores [54].
Phosphate removal on haemodialysis has been found to be time dependent [55] and thus is
significantly enhanced in NHD. Phosphate removal is also increased by SDHD but not to the
same extent as NHD [56]. In LNDHD, many patients will discontinue their phosphate binders
[57] and some require supplementation that can be added to the dialysate [58].
4.1.5. Anaemia
Reports are mixed when it comes to more frequent haemodialysis and anaemia management.
Reduced erythropoietin doses have been reported when patients switch to SDHD from CHD
[59] and in NHD [60]. One of the theories put forward for this change is the control of inflam‐
mation and reduction in IL‐6 levels which improve erythropoietin responsiveness [61]. The
exact effect that more frequent or extended dialysis has on anaemia, however, is still unclear.
Again both FHN studies showed no effect on erythropoietin dose.
4.1.6. Quality‐of‐life measures and carer burden
Home haemodialysis allows patients the independence to fit their dialysis treatment around
their lifestyles. One may expect this to bring significantly improvements to quality of life;
however, this may be offset by the burden of having to perform the treatment so frequently,
which can lead to burnout or the increased burden on carers. While there are many reports of
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improvements in quality‐of‐life measures from switching to NHD [62] or SDHD [63], some
show only small improvements in kidney‐specific measure of quality of life [64], while others
show no difference. Larger studies have shown a reduction in depressive symptoms related
to increased dialysis frequency [65].
Data from the recent FHN daily trial showed a significant increase in quality‐of‐life score in
the SDHD group [35] with no specific benefit from NHD over CHD at home. In the FHN NHD
arm, however, both groups had an increase in their quality‐of‐life score showing the positive
effect that the setting of the haemodialysis treatment has on this outcome [36] regardless of
prescription. Perceived burden on unpaid carers is high among HD patients [66]; however, the
FHN trials did not show a higher perceived burden with either SDHD or LDNHD [67].
The patient‐reported experience on both LDNHD and SDHD has been positive in terms of
physical, psychological and lifestyle aspects [68]. There is also an associated faster recovery
time with home haemodialysis [69]. Once again, it is fair to say once again that the jury is still
with regard to whether these treatments truly impact on quality of life. In general, the effect
seems to be positive with a paucity of data suggesting a negative impact.
4.1.7. Pregnancy
Intensive dialysis has been used very successfully in pregnancy. A case series from Canada
[70] shows a markedly improved live birth rate and duration of pregnancy with a dose
response between dialysis and pregnancy outcomes. Women who had >36 hours of dialysis
per week had significantly improved live birth rates (85 vs. 45% in those who had <20 hours
of dialysis per week), which again demonstrates and gives strength to high‐dose dialysis.
4.2. Disadvantages of more frequent and home haemodialysis
While there are many advantages of home haemodialysis, the treatment is not suitable for all
patients and it is not a treatment without disadvantages. Although exceedingly rare, there is
always the possibility that human error can occur resulting in significant blood loss through
a variety of mechanisms. There are reports of patient deaths from exsanguination while on
home haemodialysis [71]. The sophistication of safety mechanisms is continually improving
to make this event less likely with blood leak detectors, pressure monitoring and line discon‐
nect detectors featuring on newer machines.
A clear finding from the FHN trial was an increase in interventions needed for vascular access
with 47% of the frequent dialysis group requiring intervention compared with 29% in the CHD
group. Interventions to fistulas were required much more often than in catheters. This was not
an entirely surprising finding given the considerably increased use of vascular access form
more frequent haemodialysis. A solution to this could be the use of a buttonhole technique for
fistula cannulation or using single‐needle haemodialysis to reduce the number of needling
events. The evidence, however, is not there to support this practice and a systematic review of
buttonhole cannulation in home haemodialysis patients found an increase in infectious events,
an increase in staff support required and no reduction in surgical interventions compared with
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the “rope ladder” technique [72]. The FHN nocturnal trial used single‐needle haemodialysis,
and despite this, there was still a trend towards increased vascular interventions in this group.
Finally, globally, the uptake of extended higher frequency haemodialysis remains low, despite
a range of benefits and favourable health economics. There can be major patient and clinical
factors driving modality uptake. A key determinant, however, is patient motivation and
choice. Extended time or frequency on home HD may add to patient and carer burden and is
therefore often perceived as a barrier limiting its uptake.
5. Haemodiafiltration
Haemofiltration allows clearance of solutes of up to 20 kDa through the process of convection
as previously described. Large volumes of replacement fluid are required for the treatment,
and this can be administered either before the filter (pre‐dilution) or after the filter (post‐
dilution). Newer technology also allows a mix of pre‐ and post‐dilution or mid‐dilution in an
attempt to gain the advantages of both pre‐ and post‐dilution (largely the anticoagulant
requirement) [73].
Conventional HDF provides enhanced B2M clearance compared with HD [74]. It is associated
with a reduction in pro‐inflammatory cytokines such as IL‐6 and TNF‐α [75] and reduced
episodes of hypotension during treatment [76]. There does not appear to be a benefit in terms
of left ventricular mass, pulse wave velocity or ejection fraction [77]. This could be due to
achieving low substitution volumes or large interdialytic fluid shifts induced by conventional
thrice‐weekly schedule.
There have been three recent large prospective clinical trials, which have compared HDF with
high‐flux HD with contrasting results. The ESHOL study [78], a Spanish study, showed
promising results with a 30% lower all‐cause mortality, a 33% lower cardiovascular mortality
and 55% lower infection‐related mortality compared with haemodialysis. A Dutch study [79]
showed no difference in outcome between HDF and HD and a Turkish [80] study drew the
same conclusion. Looking back at these studies, the ESHOL study achieved the highest
convective volumes (22.9–23.9 l per session) and post hoc analyses of the Turkish and Dutch
study also show an association between high convection volume and a survival benefit.
In order to provide HDF with high convection volumes, large volumes of sterile replacement
fluid are required (>15 l), which would not be practical with pre‐packaged solutions. Instead
of online preparation of fluid, which is the most practical solution, HDF uses an additional 50–
80 l of water per session [81] (with a typical haemodialysis session using around 500 l of mains
water to generate dialysate [82]). Ultrapure dialysate must be generated by the machine to the
standards previously described.
5.1. Adding HDF in the home setting
There appears to be a benefit from high convective volume haemodiafiltration. The biggest
determinants to achieving a high convective volume are treatment time and blood flow [83].
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A blood flow between 360 and 500 ml/min is required to achieve the necessary transmembrane
pressure [84]. A well‐functioning vascular access would therefore also be required. Although
there are reports of achieving a convective volume of >20 l with a haemodialysis catheter, a
well‐functioning AV fistula would allow higher blood flows [84].
Given that treatment time is clearly an important factor in achieving the dose of HDF associated
with improved outcomes, the home setting is an ideal place to deliver the treatment. Vascular
access would not be a barrier and combining frequent haemodialysis with a convective
treatment should maximize middle molecule clearance. Switching patients from a conven‐
tional HDF schedule to a short daily schedule has been reported to result in a higher removal
of middle and large molecules, a reduction in phosphate binders, the disappearance of post‐
dialysis fatigue, an improvement in nutritional status as well as a 30% reduction in left
ventricular mass [85]. The improvements in switching to more frequent OL‐HDF are outlined
in Table 1.
Baseline Month 3 Month 6
spKt/V 2.30 ± 0.20 1.13 ± 0.15b 1.11 ± 0.11b
eKt/V 1.96 ± 0.17 0.90 ± 0.12b 0.88 ± 0.08b
URR % 84.3 ± 2.5 64.2 ± 5.3b 63.3 ± 4.2b
Weekly spKt/V 6.90 ± 0.59 6.78 ± 0.91 6.67 ± 0.64
Weekly eKt/V 5.88 ± 0.52 5.39 ± 0.75a 5.30 ± 0.50a
EKR mL/min 19.2 ± 0.5 24.2 ± 2.6b 23.8 ± 1.9b
stdKt/V 2.62 ± 0.1 3.87 ± 0.3b 3.86 ± 0.2b
Weekly URR % 253 ± 7.5 385 ± 32b 380 ± 25b
a: P<0.05;
b: P<0.01 with respect to baseline value.
Adapted from Maduell et al. [85].
Abbreviations: URR, urea reduction ratio; spKt/V, single‐pool Kt/V; eKt/V, equilibrated Kt/V; stdKt/V, standard Kt/V; TAC,
time average concentration; TAD, time average deviation; ERK, equivalent renal urea clearance.
Table 1. Change from three times a week on‐line haemodiafiltration (OL‐HDF) to short daily on‐line
haemodiafiltration (D‐OL‐HDF): comparison of urea kinetics during the two study periods.
While the technology to provide HDF in the home setting exists, it is not widely used at present
and there is very little published literature about HDF as a home therapy. Until recently, there
have not been haemodialysis machines specifically manufactured for the home market. As a
result, patients have been trained on the machines used in the main dialysis unit. Using the
same technology both in the home and in the main dialysis unit makes the logistics of
maintenance much easier. The health care team, including the technicians, are often more
comfortable and experienced using and providing support for a single machine. As technology
has developed and haemodialysis machines have become more advanced, it is important that
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more user‐friendly technology, specifically for the home market, is developed. This will allow
further uptake and expansion of home dialysis programmes.
The ideal home HD machine has been described [86] as one which is fast and easy to setup,
allows a range of prescriptions (such as short daily and nocturnal), teaches and interacts with
the patient and allows the patient to deliver intravenous fluid at the push of a button. The
description suggests the ability of the machine to re‐use blood sets and dialysers, prepare all
fluids to a standard beyond ultrapure and have the ability to provide HDF. There are many
machines in development and it is likely that this “ideal machine” will be in existence in the
near future. There is the potential for HDF machines to be complex given the choice in pre‐
dilution, post‐dilution and mixed dilution and the blood and dialysate flow. Technology
should strike a balance, remaining simple for safe use with minimal margin for error and fast
training times but also allow some flexibility to tailor treatment.
As previously described, providing a high water quality is of great importance given the high
volume that is infused into the patient. The body of evidence to support the use of ultrapure
water really lies in convective treatments, and thus, an essential requirement for any home
HDF programme will be the production of ultrapure dialysate. Water may contain both
chemical and microbiological contaminants, and in the home setting, this is likely to vary
considerably depending on the local feed water. A variety of contaminants can have clinical
consequences, such as chloramines, leading to haemolytic anaemia [87], calcium and magne‐
sium contributing to a “hard water syndrome” [88] and nitrates [89], zinc [90] and fluorides
[91] have all been documented to have potential clinical effects. After initial assessment of the
feed water and the subsequent installation of the filters and water softeners, a surveillance
programme for chemical contaminants, endotoxins and bacteria is important. This logistics of
such a programme needs to be considered as the sampling protocol, laboratory protocols and
the transport and storage of samples must all be carefully planned.
Microbiological contamination can still theoretically occur. Reverse osmosis units filter out
substances with a molecular weight > 200 kDa and thus bacterial fragments and small
endotoxins can still pass through [92]. Vigilance must be employed for unexplained febrile
episodes or signs of chronic inflammation. This would apply to both home haemodialysis and
haemodiafiltration.
Portability is an important factor for dialysis patients. Peritoneal dialysis has provided a
treatment that can be carried out virtually anywhere making the treatment appealing for
patients who work or need to travel. To date, the quantity of water and the size of the water
treatment devices has limited the portability of haemodialysis. Increasingly, there are haemo‐
dialysis machines that allow portability by utilizing sorbent technology to purify water and
thus reduce water requirements [93]. With the high convective volumes required for adequate
HDF, water requirements remain high and thus limit portability. Developments in this area
are needed allow to make HDF a more appealing home treatment for patients. Water use must
be minimized and where possible, water should be recycled. Water rejected from reverse
osmosis units can be recycled and used elsewhere in the home or dialysis unit and this is being
increasingly utilized [82].
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Anticoagulation must be a major consideration for any extracorporeal dialysis therapy. Many
patients on home haemodialysis manage well with the administration anticoagulation, and
unfractionated heparin and low molecular weight heparin are in common use. These strategies
can also be used in HDF and should not pose a barrier to home HDF use. HDF may allow
dialysis without anticoagulation through the use of pre‐dilution HDF. This may be particularly
helpful in patients with prolonged bleeding or intolerances to anticoagulation.
Today's dialysis technology enables HDF to be delivered in the home setting safely with the
production of ultra‐pure dialysate and detection of venous dislodgement. There is a growing
experience of centres using this technology [94] with a positive experience. Further details
on optimal heparinization regimes, water quality variability and its surveillance in home
HDF are necessary to define best clinical practice. It is likely that new technology coupled
with increasing HDF uptake in dialysis centres will lead on to increasing use of HDF at
home.
5.2. Economic impact of HD and HDF
Haemodialysis treatment in general is very costly, and in the United Kingdom, 1–2% of the
National Health Service budget is spent on renal care with only 0.05% with ESRF [95]. After
consumables, a large proportion of the cost is made up of direct nursing care and transportation
[96] (both of which are considerably less in home haemodialysis). Home haemodialysis has
been estimated to cost over a third less than hospital‐based haemodialysis in the United
Kingdom [96] and frequent home haemodialysis has been shown to offer a cost saving in both
Canada and Australia too [97].
In addition to the reduced transport and nursing costs, savings are also offered from a
reduction in hospital admissions [37] and a reduction in medication costs (particularly
phosphate binders) [98].
The initial setup costs of home haemodialysis are high due to the cost of training, the equipment
and installation. These initial costs are usually paid back by 14 months after which savings
occur [99], making home haemodialysis an attractive option not only from the clinical benefits
but also from the cost‐saving aspect.
Costs of high‐flux dialysers have also reduced considerably over time and high‐flux haemo‐
dialysis is now the common standard care. A UK Study looked at the costs of 34 patients
switching to OL‐HDF and 44 who remained on high‐flux HD. The cost of the treatment was
either more expensive or cheaper depending on the choice of blood lines. There was a cost
saving in the OL‐HDF group in terms of phosphate binders. Lebourg et al. [81] looked at
>28,000 dialysis treatments in a single centre and once again HDF was found to be either
cheaper or more costly (-€1.29 to +€4.58 per session) depending on treatment variables
selected. It is clear that from a cost perspective, there is little difference between HDF and
high‐flux HD.
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6. Conclusion
Home haemodialysis provides a convenient and clinically effective way of providing both
frequent and extended haemodialysis treatment. Although the hard outcome data for survival
from prospective randomized trials are lacking, it is unlikely that a larger, adequately powered
trial with sufficient follow‐up time will be feasible and the answer may need to come from
registry data. It is also time to look beyond urea clearance and towards markers, such as
convective volume and β‐trace protein, as this may pave the way to further improve haemo‐
dialysis care in the future.
However, it is clear that there are a number of clinical benefits from more frequent and
extended haemodialysis and aside from this, home haemodialysis is a treatment preferred by
many patients if choices are given [100] and a treatment that is associated with an increased
satisfaction [101].
HDF is also a feasible treatment in the home setting and is already in use. There is growing
evidence from randomized trials that dialysis patient outcomes may be improved by high‐
frequency HD and by using HDF with high convective volumes. Combining increased fre‐
quency HD with convective treatment would give patients the benefits of both small and
middle MW clearance without additional patient burden or cost implications. This may
pave the way to further improved patient outcomes; however, further randomized clinical
studies will be needed for a more definitive answer.
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